Tanaka T, Morioka Y, Gebert U
Laboratory for Pharmacology, Hoechst Japan Ltd. Saitama.
Arzneimittelforschung. 1993 May;43(5):558-62.
The effects of the novel xanthine derivative 3-ethyl-1-(6-hydroxy-6-methylheptyl)-7-propylxanthine (A90 6119, CAS 134072-58-5) on various experimentally induced ulcers was investigated in rats. A90 6119 produced a dose-dependent inhibition of gastric ulcers induced by water immersion stress and absolute ethanol with ED50- values of 2.4 and 2.8 mg/kg, p.o., respectively. The erosion induced by oral administration of 1.5% NH4OH (3 ml/rat) was significantly reduced by A90 6119 at 10 and 30 mg/kg, p.o. Likewise, A90 6119 caused a dose-dependent inhibition of gastric erosions and intestinal hemorrhage induced by platelet activating factor (PAF) with ED50- values of 8.7 and 11.9 mg/kg p.o., respectively. Duodenal ulcer induced by cysteamine was also dose-dependently inhibited by A90 6119 with an ED50-value of 0.3 mg/kg, i.p. When doses of cimetidine (200 mg/kg) and A90 6119 (10 mg/kg), equipotent in the water immersion stress model, were orally given twice daily for 5 consecutive days before the induction of gastric ulcers by stress, the H2-receptor antagonist aggravated significantly the ulcer formation while the xanthine derivative did not show such an effect. These data suggest that the 3-ethylxanthine A90 6119 possesses pronounced anti-ulcer activity and that its repeated administration might not aggravate ulcer formation and might reduce the incidence of recurrence.
在大鼠中研究了新型黄嘌呤衍生物3-乙基-1-(6-羟基-6-甲基庚基)-7-丙基黄嘌呤(A90 6119,CAS 134072-58-5)对各种实验性诱导溃疡的影响。A90 6119对水浸应激和无水乙醇诱导的胃溃疡产生剂量依赖性抑制,口服给药的半数有效量(ED50)分别为2.4和2.8mg/kg。口服1.5%氢氧化铵(3ml/只大鼠)诱导的糜烂在口服10和30mg/kg的A90 6119时显著减轻。同样,A90 6119对血小板活化因子(PAF)诱导的胃糜烂和肠出血产生剂量依赖性抑制,口服给药的ED50分别为8.7和11.9mg/kg。半胱胺诱导的十二指肠溃疡也被A90 6119剂量依赖性抑制,腹腔注射的ED50为0.3mg/kg。当在应激诱导胃溃疡前连续5天每天口服两次西咪替丁(200mg/kg)和在水浸应激模型中效力相当的A90 6119(10mg/kg)时,H2受体拮抗剂显著加重溃疡形成,而黄嘌呤衍生物未显示出这种作用。这些数据表明,3-乙基黄嘌呤A90 6119具有显著的抗溃疡活性,并且其重复给药可能不会加重溃疡形成,可能会降低复发率。